TriSalus Life Sciences CEO Mary Szela sold 4,358 shares worth nearly $18,000 in early March, slightly reducing her stake in the company. The stock recently saw a modest 1.8% rise after the company reported a small quarterly earnings beat with EPS of -$0.12 versus the expected -$0.13, and revenue in line with estimates. Analyst opinions remain mixed, with ratings ranging from sell to buy, and a consensus hold rating with a target price of $7. Hedge funds have shown some interest, but insider selling by multiple executives suggests cautious sentiment. TriSalus focuses on non-invasive cancer therapies and continues clinical trials for its drug-device combination treatments.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Ethereum (ETH) surged past the $1,894.89 resistance level, accelerating its recovery toward the $1,940–$1,950 zone after days of consolidation. This breakout was supported by lower-than-expected U.S. inflation data, which boosted risk appetite and bu...
Allied Critical Metals announced positive assay results from its 2026 drilling campaign at the Santa Helena Breccia, part of the Borralha Tungsten Project in Portugal. The first drill hole confirmed broad zones of high-grade tungsten mineralization, ...
Ethereum's price rose about 11% over the past week to around $1,920, outperforming major cryptocurrencies like Bitcoin and Solana. This rally is fueled by $96 million inflows into U.S. spot Ether ETFs early in the week, with BlackRock's ETHA product ...
The XRP Ledger has surpassed 8 million activated accounts, marking steady growth since March 2026. However, daily active addresses have declined to a 2026 low of 25,350, indicating less frequent user engagement despite overall adoption. XRP's price f...
